Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 4/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.41 |
| ▸ | MMP1 | P03956 | 3/20 | 0.41 |
| ▸ | MMP2 | P08253 | 3/20 | 0.41 |
| ▸ | MMP3 | P08254 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16201781 | 0.91 | TSHR (0.41) | MMP2MMP3MAPT | |
| SCHEMBL16201772 | 0.91 | TSHR (0.41) | MMP2MMP3MAPT | |
| SCHEMBL1114734 | 0.81 | MAPT (0.40) | MAPT | |
| SCHEMBL1975707 | 0.81 | MAPT (0.40) | MAPT | |
| SCHEMBL16201797 | 0.81 | FAAH (0.40) | FAAHMAPT | |
| SCHEMBL16201801 | 0.79 | GRIK1 (0.43) | FAAHTRPA1MMP2MMP3MAPT | |
| SCHEMBL16201821 | 0.79 | GRIK1 (0.43) | FAAHTRPA1MMP2MMP3MAPT | |
| SCHEMBL8089064 | 0.78 | FAAH (0.51) | FAAHTRPA1MAPTRXFP1ALOX5 | |
| SCHEMBL7326178 | 0.77 | KMT2A (0.48) | FAAHPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL864449 | 0.76 | FAAH (0.54) | FAAHTRPA1MAPTRXFP1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0871439-B1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | AVENTIS PHARMA INC (US) | 2004-03-31 | — | — | EP | disclosed |
| US-6057369-A | USE IN THE TREATMENT OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY WHICH ARE CAPABLE OF BEING MODULATED BY INHIBITING A MATRIX METALLOPROTEINASE (MMP), TUMOR NECROSIS FACTOR (TNF) OR CYCLIC AMP | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0871439-A4 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE POULENC RORER PHARMA (US) | 1999-07-21 | — | — | EP | disclosed |
| EP-0871439-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997024117-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-10 | — | — | WO | disclosed |